Results 121 to 130 of about 18,434 (234)

Improvement in Myoclonus-Dystonia Syndrome during Treatment with Gonadotropin-Releasing Hormone Agonist. [PDF]

Mov Disord Clin Pract, 2023
Moura J, Magalhães M.
europepmc   +1 more source

Gonadotropin releasing hormone agonist for chronic anovulatory uterine bleeding and severe anemia

, 1993
Twenty-three women with chronic heavy anovulatory uterine bleeding and severe iron-deficiency anemia received six months' treatment with goserelin, a gonadotropin releasing hormone agonist, administered as a monthly subcutaneous depot.
A. Colombo, R. Maggi, L. Bocciolone, L. Fedele, P. Vercellini, N. Vendola   +5 more
core  

The involvement of central corticotropin-releasing hormone and its receptors in sleep-wake regulation of mice [PDF]

, 2010
The corticotropin-releasing hormone (CRH) is widely recognised as the major activator of the hypothalamic-pituitary-adrenocortical (HPA) axis, thereby mediating neuroendocrine, autonomic, and behavioural responses to stress.
Romanowski, C., Romanowski, Christoph P. N., Romanowski, Christoph   +2 more
core  

Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort

Cancer Management and Research, 2011
E David Crawford, Jason M PhillipsUniversity of Colorado Health Sciences Center, Aurora, CO, USAAbstract: Two different 6-month GnRH agonist depot formulations approved for palliative treatment of advanced and metastatic prostate cancer in the United ...
Phillips JM, Crawford ED
doaj  

Gonadotropin-Releasing Hormone Agonist [PDF]

, 2008
openaire   +1 more source

Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial. [PDF]

Clin Exp Pediatr
Lerdrassameethad W, Wacharasindhu S, Supornsilchai V, Srilanchakon K.   +3 more
europepmc   +1 more source

Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study

, 2018
Background: The use of embryo cryopreservation excludes the possible detrimental effects of ovarian stimulation on the endometrium, and higher reproductive outcomes following this policy have been reported.
Mahnaz Mansoori-Torshizi, Behrouz Aflatoonian, Mohammaad Ali Khalili, Peter Humaidan, Mohammad Hossein Amir-Arjmand, Nasim Tabibnejad, Nastaran Aflatoonian, Abbas Aflatoonian, Mehrdad Soleimani, Maryam Farid Mojtahedi, Homa Oskouian   +10 more
core  

Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis. [PDF]

Breast Cancer Res Treat
de Liz CD, Reis PCA, Blanchard-Cavagis ER, Diniz IC, Brito HC, Visani FLV.   +5 more
europepmc   +1 more source

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer. [PDF]

JCEM Case Rep, 2023
Mastandrea K, Voica M, Tetlay M, Hasan F.   +3 more
europepmc   +1 more source

Final adult height in male patients with central precocious puberty after gonadotropin-releasing hormone agonist treatment. [PDF]

Ann Pediatr Endocrinol Metab
Cho KW, Kim YK, Yoo JE, Kim JY, Kim SJ, Kim S, Choi Y, Song K, Lee EB, Chae HW, Suh J.   +10 more
europepmc   +1 more source